Published in Diabetologia on June 08, 2010
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 1.82
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care (2014) 1.68
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ (2012) 1.50
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Metformin in cancer prevention and therapy. Ann Transl Med (2014) 1.18
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. Br J Cancer (2015) 1.04
Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY) (2012) 1.04
Risk of cancer in diabetes: the effect of metformin. ISRN Endocrinol (2013) 1.04
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol (2011) 0.95
Clinical benefits of metformin in gynecologic oncology. Oncol Lett (2015) 0.91
Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One (2014) 0.91
Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis. Medicine (Baltimore) (2016) 0.90
Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. Metabolites (2013) 0.89
Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning. Oncol Lett (2016) 0.89
Metformin effects revisited. Diabetes Res Clin Pract (2011) 0.88
Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One (2015) 0.86
Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open (2014) 0.86
Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab (2011) 0.83
Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
Safety of PPAR agonists. Diabetes Care (2011) 0.82
Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol (2012) 0.82
Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer (2014) 0.80
A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. BMC Med Genomics (2014) 0.79
Adiponectin improves NF-κB-mediated inflammation and abates atherosclerosis progression in apolipoprotein E-deficient mice. Lipids Health Dis (2016) 0.78
Syrosingopine sensitizes cancer cells to killing by metformin. Sci Adv (2016) 0.78
Validity of meta-analysis in diabetes: we need to be aware of its limitations. Diabetes Care (2013) 0.78
Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies. PLoS One (2013) 0.78
Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Sci Rep (2016) 0.76
Metformin and colorectal cancer risk in diabetic patients. Diabetes Care (2011) 0.76
Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology (2017) 0.75
Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PLoS One (2014) 0.75
Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Oncotarget (2016) 0.75
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore) (2017) 0.75
Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med (2017) 0.75
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health (1999) 5.21
Does diabetes therapy influence the risk of cancer? Diabetologia (2009) 3.66
The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology (2007) 3.60
Contra-indications to metformin therapy are largely disregarded. Diabet Med (1999) 1.41
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia (2003) 5.91
Function of an ophthalmic "accident and emergency" department: results of a six month survey. Br Med J (Clin Res Ed) (1986) 4.11
Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study. Diabetologia (1999) 3.64
Comparison of blood pressure measurement methods in adult diabetics. Lancet (1997) 3.31
Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ (2001) 3.12
Frosted branch angiitis: a review. Eye (Lond) (2004) 2.66
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia (2012) 2.53
The epidemic of type 2 diabetes is a statistical artefact. Diabetologia (2005) 2.41
Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia (1997) 2.41
Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ (1995) 2.40
A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery. Anaesthesia (1997) 2.35
Early closure of European Pimagedine trial. Steering Committee. Safety Committee. Lancet (1997) 2.28
Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia (2005) 2.23
Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia (2010) 2.21
Uveitis and the menstrual cycle. Eye (Lond) (2004) 2.10
Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes (1993) 2.03
Waiting times and the patient's charter. BMJ (1994) 1.99
Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest (1992) 1.96
Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet (1993) 1.95
Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens (2003) 1.95
Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci U S A (1996) 1.80
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest (1994) 1.79
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 1.75
beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes (2001) 1.74
The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest (2002) 1.70
Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care (1996) 1.68
Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia (2007) 1.67
Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest (1993) 1.67
Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia (2001) 1.65
Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology (1992) 1.65
Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia (2010) 1.64
Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med (1985) 1.60
Vascular responsiveness and cation exchange in insulin-dependent diabetes. Clin Sci (Lond) (1991) 1.60
Impaired insulin-induced site-specific phosphorylation of TBC1 domain family, member 4 (TBC1D4) in skeletal muscle of type 2 diabetes patients is restored by endurance exercise-training. Diabetologia (2010) 1.57
Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism. J Clin Invest (1987) 1.56
Ocular syphilis: the new epidemic. Eye (Lond) (2005) 1.56
Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia (2009) 1.55
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med (2004) 1.54
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes (2011) 1.53
Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes (1996) 1.52
Eye injuries in racquet sports. BMJ (1991) 1.51
Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation. Diabetologia (2005) 1.50
The new Danish Twin Register: establishment and analysis of twinning rates. Int J Epidemiol (1995) 1.50
Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia (1991) 1.49
Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes (2000) 1.48
Clinical impact of mild carbohydrate intolerance in pregnancy: a study of 2904 nondiabetic Danish women with risk factors for gestational diabetes mellitus. Am J Obstet Gynecol (2001) 1.47
The safety and effectiveness of remifentanil as an adjunct sedative for regional anesthesia. Anesth Analg (1999) 1.46
Does zygosity influence the metabolic profile of twins? A population based cross sectional study. BMJ (1999) 1.46
The 1988 earthquake in Soviet Armenia: a case study. Ann Emerg Med (1990) 1.45
Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes (2001) 1.42
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.41
Spontaneous sub-conjunctival haemorrhage in patients using long-term topical corticosteroids. Eye (Lond) (2010) 1.39
Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1998) 1.38
GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease? Diabetes (2001) 1.38
Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab (1999) 1.37
Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Clin Invest (1991) 1.36
The patterns of proteinuria in diabetes mellitus. Relevance to pathogenesis and prevention of diabetic nephropathy. Diabetes (1984) 1.35
Morphometric documentation of abnormal intramyocellular fat storage and reduced glycogen in obese patients with Type II diabetes. Diabetologia (2001) 1.34
Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes (1991) 1.34
Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes (2004) 1.31
Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes (1999) 1.31
Kinetics and specificity of insulin uptake from plasma into cerebrospinal fluid. Am J Physiol (1990) 1.31
Expression of insulin regulatable glucose transporters in skeletal muscle from type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1990) 1.30
Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes (1992) 1.28
Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia (2008) 1.27
On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion. Diabetologia (1990) 1.26
Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. Diabetes (1999) 1.26
The visceral adiposity syndrome in Japanese-American men. Obes Res (1994) 1.26
Correction of exercise-induced microalbuminuria in insulin-dependent diabetics after 3 weeks of subcutaneous insulin infusion. Diabetes (1981) 1.24
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet Med (2006) 1.24
Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. Am J Clin Nutr (1980) 1.24
Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets. Diabetologia (2008) 1.22
Lumbar vertebral body compressive strength evaluated by dual-energy X-ray absorptiometry, quantitative computed tomography, and ashing. Bone (1999) 1.22
Glycaemia, arterial pressure and micro-albuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1984) 1.22
Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes (1994) 1.21
Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM. Diabetes (1988) 1.21
Reduced insulin secretion: an independent predictor of body weight gain. J Clin Endocrinol Metab (1995) 1.21
Severe eye injuries in cricket. Br J Sports Med (1986) 1.21
Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab (1999) 1.20
Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme function in B-cell signaling. J Biol Chem (2001) 1.19
Age-dependent impact of zygosity and birth weight on insulin secretion and insulin action in twins. Diabetologia (2002) 1.19
Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia (1996) 1.17
Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest (1995) 1.17
Glomerular response mechanisms to glycemic changes in insulin-dependent diabetics. Kidney Int (1987) 1.15
A cellular model system of differentiated human myotubes. APMIS (2001) 1.15
Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia (2005) 1.15
Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes (2001) 1.15
Consent for genetics studies among clinical trial participants: findings from Action for Health in Diabetes (Look AHEAD). Clin Trials (2006) 1.15
Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care (1989) 1.13
Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia (2011) 1.13
Intra-abdominal fat accumulation predicts the development of the metabolic syndrome in non-diabetic Japanese-Americans. Diabetologia (2007) 1.12
Evidence for entry of plasma insulin into cerebrospinal fluid through an intermediate compartment in dogs. Quantitative aspects and implications for transport. J Clin Invest (1991) 1.12
No association between birth weight and Type 1 diabetes mellitus--a twin-control study. Diabet Med (2000) 1.11
Effect of physical training on mitochondrial respiration and reactive oxygen species release in skeletal muscle in patients with obesity and type 2 diabetes. Diabetologia (2010) 1.11
Confirming glycemic status in the Diabetes Prevention Program: implications for diagnosing diabetes in high risk adults. J Diabetes Complications (2012) 1.11